Atherosclerosis is a chronic disease of the arterial wall where both innate and adaptive immunoinflammatory mechanisms are involved. Inflammation is central at all stages of atherosclerosis. It is implicated in the formation of early fatty streaks, when the endothelium is activated and expresses chemokines and adhesion molecules leading to monocyte/lymphocyte recruitment and infiltration into the subendothelium. It also acts at the onset of adverse clinical vascular events, when activated cells within the plaque secrete matrix proteases that degrade extracellular matrix proteins and weaken the fibrous cap, leading to rupture and thrombus formation. Cells involved in the atherosclerotic process secrete and are activated by soluble factors, known as cytokines. Important recent advances in the comprehension of the mechanisms of atherosclerosis provided evidence that the immunoinflammatory response in atherosclerosis is modulated by regulatory pathways, in which the two anti-inflammatory cytokines interleukin-10 and transforming growth factor-beta play a critical role. The purpose of this review is to bring together the current information concerning the role of cytokines in the development, progression, and complications of atherosclerosis. Specific emphasis is placed on the contribution of pro- and anti-inflammatory cytokines to pathogenic (innate and adaptive) and regulatory immunity in the context of atherosclerosis. Based on our current knowledge of the role of cytokines in atherosclerosis, we propose some novel therapeutic strategies to combat this disease. In addition, we discuss the potential of circulating cytokine levels as biomarkers of coronary artery disease.

/pdf/cytokines-in-atherosclerosis-pathogenic-and-regulatory-k5l4m0ggqp.pdf

Cytokines in atherosclerosis: pathogenic and regulatory pathways.

Monocytes participate critically in atherosclerosis. There are 2 major subsets expressing different chemokine receptor patterns: CCR2(+)CX3CR1(+)Ly-6C(hi) and CCR2(-)CX3CR1(++)Ly-6C(lo) monocytes. Both C-C motif chemokine receptor 2 (CCR2) and C-X(3)-C motif chemokine receptor 1 (CX3CR1) are linked to progression of atherosclerotic plaques. Here, we analyzed mouse monocyte subsets in apoE-deficient mice and traced their differentiation and chemokine receptor usage as they accumulated within atherosclerotic plaques. Blood monocyte counts were elevated in apoE(-/-) mice and skewed toward an increased frequency of CCR2(+)Ly-6C(hi) monocytes in apoE(-/-) mice fed a high-fat diet. CCR2(+)Ly-6C(hi) monocytes efficiently accumulated in plaques, whereas CCR2(-)Ly-6C(lo) monocytes entered less frequently but were more prone to developing into plaque cells expressing the dendritic cell-associated marker CD11c, indicating that phagocyte heterogeneity in plaques is linked to distinct types of entering monocytes. CCR2(-) monocytes did not rely on CX3CR1 to enter plaques. Instead, they were partially dependent upon CCR5, which they selectively upregulated in apoE(-/-) mice. By comparison, CCR2(+)Ly-6C(hi) monocytes unexpectedly required CX3CR1 in addition to CCR2 and CCR5 to accumulate within plaques. In many other inflammatory settings, these monocytes utilize CCR2, but not CX3CR1, for trafficking. Thus, antagonizing CX3CR1 may be effective therapeutically in ameliorating CCR2(+) monocyte recruitment to plaques without impairing their CCR2-dependent responses to inflammation overall.

https://dm5migu4zj3pb.cloudfront.net/manuscripts/28000/28549/JCI0728549.v1.pdf

Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques

From the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor (M.P.-G.); and the Center for Allergy and Inflammation, Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle (W.R.H.). Address reprint requests to Dr. Peters-Golden at the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, 6301 MSRB III, 1150 W. Medical Center Dr., Ann Arbor, MI 48109-5642, or at petersm@umich.edu.

Mechanisms of disease: Leukotrienes

4. Biosynthesis of Leukotrienes 5869 4.1. Discovery of the Leukotriene Pathway and a Common Unstable Intermediate 5869 4.2. Conversion of Arachidonic Acid into Leukotriene A4 (LTA4) Is a Two-Step Concerted Reaction Catalyzed by a Single Lipoxygenase 5869 4.3. Structural Elucidation of Slow-Reacting Substance of Anaphylaxis, A Mixture of Leukotrienes 5870 5. Enzymes and Proteins in Leukotriene Biosynthesis 5870 5.1. Cytosolic Phospholipase A2α (cPLA2α) 5870 5.1.1. Molecular Properties and Regulation of cPLA2α 5870 5.1.2. Crystal Structure and Catalytic Mechanism of cPLA2α 5871 5.2. 5-Lipoxygenase (5-LO) 5871 5.2.1. Cellular Expression of 5-LO 5871 5.2.2. Regulation of 5-LO Gene (ALOX5) Transcription 5872 5.2.3. Naturally Occurring Mutations in the Gene Promoter of 5-LO 5872 5.2.4. Allosteric and Post-translational Regulation of 5-LO 5872 5.2.5. Structure function relationships in 5-LO 5872 5.2.6. Crystal Structure of 5-LO 5872 5.3. 5-Lipoxygenase-Activating Protein (FLAP) 5873 5.3.1. FLAP Is Critical for Cellular 5-LO Activity 5873 5.3.2. Effects of FLAP on Leukotriene Production 5873 5.3.3. FLAP Gene (ALOX5AP) and Regulation of Expression 5874 5.3.4. Crystal Structure of FLAP 5874 5.4. LTA4 Hydrolase 5874 5.4.1. LTA4 Hydrolase Is a Substrate-Selective and Suicide-Inactivated Epoxide Hydrolase 5874 5.4.2. LTA4 Hydrolase Is Bifunctional and Belongs to the M1 Family of Zinc Metallopeptidases 5874 5.4.3. LTA4 Hydrolase Cleaves the Chemotactic Pro-Gly-Pro, a Role for the Aminopeptidase Activity during Resolution of Inflammation 5875 5.4.4. Crystal Structure of LTA4 Hydrolase 5875 5.4.5. Mechanism of the Epoxide Hydrolase Reaction 5876 5.4.6. Mechanism of the Aminopeptidase Activity 5876 5.4.7. Two Catalytic Activities Exerted via Specific but Overlapping Active Sites 5877 5.5. LTC4 Synthase 5877 5.5.1. Molecular Properties of LTC4 Synthase 5877 5.5.2. LTC4 Synthase Is a Member of the MAPEG Superfamily of IntegralMembraneProteins 5877 5.5.3. Gene Structure and Regulation of LTC4 Synthase Expression 5877 5.5.4. Crystal Structure of LTC4 Synthase 5877 5.5.5. Catalytic Mechanism of LTC4 Synthase 5878 6. Intracellular Protein Trafficking and Compartmentalization of Leukotriene Biosynthesis 5878 6.1. Translocation of cPLA2α 5878 6.2. Translocation of 5-LO and Association with FLAP on the Nuclear Envelope 5879 6.2.1. 5-LO in the Nucleoplasm 5879 6.2.2. Organization of a Leukotriene Biosynthetic Complex in the Nuclear Membrane 5879 6.3. Leukotriene Biosynthesis in Lipid Bodies and Actions on Extracellular Granules 5879

Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease.

The arachidonic acid (AA) pathway plays a key role in cardiovascular biology, carcinogenesis, and many inflammatory diseases, such as asthma, arthritis, etc. Esterified AA on the inner surface of the cell membrane is hydrolyzed to its free form by phospholipase A2 (PLA2), which is in turn further metabolized by cyclooxygenases (COXs) and lipoxygenases (LOXs) and cytochrome P450 (CYP) enzymes to a spectrum of bioactive mediators that includes prostanoids, leukotrienes (LTs), epoxyeicosatrienoic acids (EETs), dihydroxyeicosatetraenoic acid (diHETEs), eicosatetraenoic acids (ETEs), and lipoxins (LXs). Many of the latter mediators are considered to be novel preventive and therapeutic targets for cardiovascular diseases (CVD), cancers, and inflammatory diseases. This review sets out to summarize the physiological and pathophysiological importance of the AA metabolizing pathways and outline the molecular mechanisms underlying the actions of AA related to its three main metabolic pathways in CVD and cancer progression will provide valuable insight for developing new therapeutic drugs for CVD and anti-cancer agents such as inhibitors of EETs or 2J2. Thus, we herein present a synopsis of AA metabolism in human health, cardiovascular and cancer biology, and the signaling pathways involved in these processes. To explore the role of the AA metabolism and potential therapies, we also introduce the current newly clinical studies targeting AA metabolisms in the different disease conditions.

/pdf/metabolism-pathways-of-arachidonic-acids-mechanisms-and-26csrabpai.pdf

Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets.

Activation of the 5-lipoxygenase (5-LO) pathway leads to the biosynthesis of proinflammatory leukotriene lipid mediators. Genetic studies have associated 5-LO and its accessory protein, 5-LO-activating protein, with cardiovascular disease, myocardial infarction and stroke. Here we show that 5-LO-positive macrophages localize to the adventitia of diseased mouse and human arteries in areas of neoangiogenesis and that these cells constitute a main component of aortic aneurysms induced by an atherogenic diet containing cholate in mice deficient in apolipoprotein E. 5-LO deficiency markedly attenuates the formation of these aneurysms and is associated with reduced matrix metalloproteinase-2 activity and diminished plasma macrophage inflammatory protein-1alpha (MIP-1alpha; also called CCL3), but only minimally affects the formation of lipid-rich lesions. The leukotriene LTD(4) strongly stimulates expression of MIP-1alpha in macrophages and MIP-2 (also called CXCL2) in endothelial cells. These data link the 5-LO pathway to hyperlipidemia-dependent inflammation of the arterial wall and to pathogenesis of aortic aneurysms through a potential chemokine intermediary route.

The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm

Handle everyday research tasks with reliable, citation-backed results

Your personal Research Agent to handle research tasks with citation-backed results

Popular Tasks used by Researchers

How can I help with your research?

Meet SciSpace

Get more enhanced response by uploading the PDFs you want me to reference.

No relevant PDFs in your library

SciSpace is the AI research assistant for academics. Run systematic literature reviews on 280M+ papers, and write papers with cited sources. Trusted by 1M+ students, PhDs & researchers.

SciSpace | AI for Research

Analyze PDFs

Code & Manuscripts

Funding & Grants

Literature & Patents

Medical & Clinical Data

Systematic Review

Visualize & Present

Web & Data

Build a Google Scholar-like website for your research.

Build a website

Create charts and images for your research

Create a Chart

Write a paper for submission to a journal

Draft a manuscript

Patent Search

Design eye-catching scientific posters in minutes.

Scientific Poster Generation

Systematic Literature Review

One task is running at the moment. Your messages will be shown right after.

Drag and drop or click here to browse

Loved by <highlight>1 million+</highlight> researchers

Extract a list of specific topics and their sources from unstructured text

Topics

Compare and analyze relevant papers that matches with your search

Papers

Get insights from PDFs and bookmarked papers from your library

My library

Recent searches

Try searching for:

Catch AI-generated content in scholarly and non-scholarly content

{ai} Detector

Ai Writer

Get PDF Summaries, highlighted text explanations 

Chat with PDF

Effortlessly create in-text citations and bibliographies in APA and 2,500 other formats

Citation generator

Get explanations, summaries, and answers on academic papers

Ease up your research workflow with {scispace}'s cohort of exciting AI tools

Elevate your academic writing skills and convey your ideas the way you want

Paraphraser

Explore our range of reading and writing tools

Your file is being prepared and should be ready in a few minutes. If it's a large file, it might take a bit longer. You can close this window, and we'll email you the file when it's done.

You have reached a maximum limit of <strong>{limit}</strong> columns in the table. Remove at least <strong>1</strong> column to add or create another one.

Sandra Schmidt

Author Tools

Chat about Author

Papers

The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm